Clinical Trials Logo

Clinical Trial Summary

Antalgic treatment of painful bone metastases by US-guided High Intensity Focused Ultrasound (HIFU).


Clinical Trial Description

Inclusion Criteria

- 18 years of age or older.

- Histologically proven malignancy of primary tumor. Histologic diagnosis may be established from needle biopsy, cytology, or a surgical biopsy or resection. If the nature of the lesion has been previously through biopsy, the lesion to be treated does not require further documentation.

- Metastatic disease documented either by imaging techniques (plain radiographs, radionuclide bone scans, computed tomography scans and magnetic resonance imaging) or by histology. Other imaging techniques may be acceptable with the approval of the principal investigator.

- ≤ 3 treatable painful bone metastases.

- "Worst Pain Score" of > 3 on a scale of 10 during a 24-hour period (as scored on the Brief Pain Inventory [BPI] question #3: 0 = no pain; 10 = worst possible pain) despite level II analgesic medications.

- Prothrombin time (PT) >50%, Thrombocytes >50x109/L.

- Estimated life expectancy of 3 months or greater, as estimated by the responsible clinician.

- Targeted tumor clearly visible in B-mode ultrasonography, and accessible to US-HIFU treatment, based on imaging data.

- Agreement from the anaesthetist for a IV conscious sedation

- Signed study-specific informed consent prior to inclusion.

- Negative pregnancy test before inclusion for women of childbearing and or efficient method of contraception.

- Patient with social security coverage. Biphosphonate, chemotherapy or hormone therapy intake should remain stable (if possible) throughout follow-up duration.

Exclusion criteria for subject selection

- Pregnant or lactating women.

- Radiation therapy to the targeted sites within 30 days prior to enrollment.

- Targeted tumor mass is less than 10 mm from spinal cord, nerve bundles, bladder, bowel, or hollow viscera,

- Targeted tumor located in skull (including facial bones), vertebral body or sternum.

- Site at need for surgical stabilization

- Uncontrolled bleeding disorders.

- Hematologic primary malignancies.

- patient participating in other trials using drugs or devices ;


Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care


Related Conditions & MeSH terms


NCT number NCT01765907
Study type Interventional
Source Theraclion
Contact
Status Completed
Phase Phase 1
Start date December 2012
Completion date March 2014

See also
  Status Clinical Trial Phase
Completed NCT01833806 - A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain N/A
Terminated NCT01586273 - Multicenter Study of Magnetic Resonance-guided High Intensity Focused Ultrasound for Pain Palliation of Bone Metastases N/A
Completed NCT02609828 - Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy Phase 3
Completed NCT04592887 - Feasibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases N/A
Recruiting NCT02231476 - Efficacy of Radiotherapy in Combination With Zoledronic Acid on Pain Relief in Bone Metastasis Patients Phase 2
Recruiting NCT02426697 - Pain Management With Pecfent in the Prevention of Pain Induced by Position in Radiotherapy Phase 3
Completed NCT00334139 - Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer Phase 4
Completed NCT01784393 - Chemoradiation for Bone Metastasis Phase 2
Terminated NCT02999152 - Validation of Radio-induced Damage Biomarkers N/A
Not yet recruiting NCT02480634 - Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer Phase 4
Completed NCT02784652 - Efficacy of Radiotherapy in Combination With Zoledronic Acid in Bone Metastasis Patients With Gastrointestinal Tumors Phase 2
Completed NCT02774213 - A Study to Collect Data About Analgesia in Patients With Bone Metastasis
Completed NCT02673060 - A Trial of MBC-11 in Patients With CIBD Phase 1
Completed NCT02876731 - Comparison of NaF PET-CT and Diffusion MRI in the Diagnosis of Bone Metastases (IMMETAOS) N/A
Recruiting NCT02705157 - The OPTIMAL Study - A Prospective Cohort of Patients With Bone Metastases of the Long Bones N/A
Completed NCT01309048 - Magnetic Resonance-Guided High Intensity Focused Ultrasound for Palliation of Painful Skeletal Metastases Phase 1/Phase 2
Completed NCT01062503 - Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC N/A
Completed NCT00610272 - Optimization of Radiotherapy in Treatment of Painful Bone Metastasis Phase 3
Completed NCT01998607 - Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw N/A
Recruiting NCT02876991 - Evaluation of Sodium Fluoride PET in the Identification of Bone Metastases in Patients Having Undergone a Choline PET for Occult Recurrence of Prostatic Adenocarcinoma N/A